sur Zomedica Corp. (NASDAQ:ZOM)
Zomedica Unveils Equine Asthma Clinical Registry
Zomedica Corp., a veterinary health company, has launched the Equine Asthma Clinical Registry, an initiative aimed at addressing asthma in horses using PulseVet® shock wave therapy. This approach offers a non-invasive and drug-free alternative for asthma treatment in horses, a condition affecting approximately 15% of horses over seven years old.
The registry seeks to gather clinical data to improve treatment strategies. Studies indicate that the PulseVet system's electrohydraulic extracorporeal shock wave therapy (ESWT) significantly enhances respiratory health in affected horses, with 58 horses having completed treatment without adverse effects.
Dr. Beau Whitaker from Brazos Valley Equine Hospital noted improvements in clinical signs following ESWT treatment. Clinics can enroll up to 20 horses, aiding research while gaining product credits. This registry underscores Zomedica's commitment to advancing veterinary care through evidence-based solutions.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Zomedica Corp.